Loading
Immunotherapy and Immune Responses / CAR-T Cell Therapy Research · Journal article
Cancers · August 18, 2026
Encouraging direction, but not yet definitive.
This preclinical study in a murine glioma model demonstrates that dendritic cell dysfunction, rather than T cell exhaustion, is a key mechanism of tumor recurrence after adoptive cellular therapy. Hypoxia-driven tolerization of DCs impairs their ability to activate T cells, and HIF1α disruption partially reverses this effect, suggesting the hypoxia–DC axis as a potential therapeutic target.
Preclinical mechanistic study in murine glioma model with flow cytometry, transcriptomic analysis, and functional assays. C57BL/6 mice implanted with KR158B-luc murine glioma cells. Intervention: Adoptive cellular therapy comprising tumor RNA-pulsed dendritic cell vaccine and adoptively transferred T cells; HIF1α CRISPR-mediated knock-out in vitro. Compared with: Untreated controls (implied); wild-type dendritic cells exposed to hypoxia versus HIF1α-disrupted dendritic cells.
ACT significantly increased survival but did not prevent tumor recurrence in the murine model Escaped tumors contained abundant cytotoxic, non-exhausted T cells, indicating T cell dysfunction was not the primary driver of recurrence Tumor-associated DCs exhibited impaired T cell activation despite preserved antigen uptake
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These findings suggest that strategies targeting DC function and hypoxia signaling may enhance adoptive cellular therapy efficacy in glioblastoma. The identification of DC dysfunction as the primary mechanism of immune escape offers a rationale for combination approaches, but human validation is needed before clinical translation.
Mechanistic study in a murine model identifying dendritic cell dysfunction and hypoxia as drivers of immune escape after adoptive cellular therapy, with functional validation but limited to preclinical findings.
As stated by the source record.
These findings suggest that strategies targeting DC function and hypoxia signaling may enhance adoptive cellular therapy efficacy in glioblastoma. The identification of DC dysfunction as the primary mechanism of immune escape offers a rationale for combination approaches, but human validation is needed before clinical translation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Background/Objectives: Glioblastoma (GBM) remains a lethal primary CNS malignancy with limited response to immunotherapy. Adoptive cellular therapy (ACT) improves survival in preclinical models, yet tumors ultimately recur. While T cell exhaustion is a common mechanism of resistance, the contribution of dendritic cell (DC) dysfunction remains unclear. We aimed to define mechanisms of immune escape following ACT, focusing on DC function and the role of hypoxia. Methods: Using a murine glioma model (KR158B-luc), mice were treated with ACT consisting of tumor RNA-pulsed DC vaccines and adoptively transferred T cells. Tumor-infiltrating immune populations were analyzed by flow cytometry. DC function was assessed using T cell activation assays. Bulk RNA sequencing and gene set enrichment analysis were performed on sorted DCs. Hypoxia was modeled in vitro, and HIF1α was perturbed using CRISPR-mediated knock-out. Results: ACT significantly increased survival but did not prevent tumor recurrence. Escaped tumors contained abundant cytotoxic, non-exhausted T cells, indicating that T cell dysfunction was not the primary driver of recurrence under ACT. Instead, tumor-associated DCs exhibited impaired T cell activation despite preserved antigen uptake. Transcriptomic analyses revealed reduced antigen presentation and co-stimulatory signaling, alongside increased expression of tolerogenic factors. ACT-treated tumors demonstrated heightened hypoxia pathway activation, with elevated HIF1α expression in DCs. Hypoxia induced DC tolerogenic programs and reduced their ability to activate T cells, an effect partially reversed by HIF1α disruption. Increased immune infiltration and inflammation following ACT further amplified hypoxia signaling and enhanced DC tolerance. Conclusions: DC dysfunction is one of the key mechanisms of immune escape following ACT in glioma. Hypoxia-driven tolerization of DCs impairs sustained anti-tumor immunity, highlighting the hypoxia–DC axis as a promising therapeutic target to enhance immunotherapy efficacy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.